These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7784909)

  • 1. The costs and benefits of a vaccination programme for Haemophilus influenzae type B disease.
    Hussey GD; Lasser ML; Reekie WD
    S Afr Med J; 1995 Jan; 85(1):20-5. PubMed ID: 7784909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.
    Harris A; Hendrie D; Bower C; Payne J; de Klerk N; Stanley F
    Med J Aust; 1994 Apr; 160(8):483-8. PubMed ID: 8170423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-preventable haemophilus influenza type B disease burden and cost-effectiveness of infant vaccination in Indonesia.
    Gessner BD; Sedyaningsih ER; Griffiths UK; Sutanto A; Linehan M; Mercer D; Mulholland EK; Walker DG; Steinhoff M; Nadjib M
    Pediatr Infect Dis J; 2008 May; 27(5):438-43. PubMed ID: 18398383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An assessment of the value of Haemophilus influenzae type b conjugate vaccine in Asia.
    Miller MA
    Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S152-9. PubMed ID: 9781750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An economic analysis of alternatives for childhood immunisation against Haemophilus influenzae type b disease.
    McIntyre P; Hall J; Leeder S
    Aust J Public Health; 1994 Dec; 18(4):394-400. PubMed ID: 7718653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis.
    Zhou F; Bisgard KM; Yusuf HR; Deuson RR; Bath SK; Murphy TV
    Pediatrics; 2002 Oct; 110(4):653-61. PubMed ID: 12359777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines.
    Matjila MJ; Phohu TC; Banzhoff A; Viviani S; Hoosen AA; Bianchini M; Nacci P; Palweni CW; Podda A; Whitfield M; Aspinall S
    S Afr Med J; 2004 Jan; 94(1):43-6. PubMed ID: 14971232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Haemophilus influenzae type b conjugate vaccine program in Florida.
    Midani S; Ayoub EM; Rathore MH
    J Fla Med Assoc; 1995 Jun; 82(6):401-2. PubMed ID: 7643054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India.
    Gupta M; Prinja S; Kumar R; Kaur M
    Health Policy Plan; 2013 Jan; 28(1):51-61. PubMed ID: 22407018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
    Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
    Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Costs and benefits of vaccination against Haemophilus influenzae type b].
    Martens LL; ten Velden GH; Bol P
    Ned Tijdschr Geneeskd; 1991 Jan; 135(1):16-20. PubMed ID: 1899290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of general childhood vaccination against Haemophilus influenzae type b in Sweden.
    Garpenholt O; Silfverdal SA; Levin LA
    Scand J Infect Dis; 1998; 30(1):5-10. PubMed ID: 9670351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.
    Ginsberg GM; Kassis I; Dagan R
    J Epidemiol Community Health; 1993 Dec; 47(6):485-90. PubMed ID: 8120505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The cost-effectiveness of Haemophilus influenzae type b vaccine for children under 2 years of age in Colombia].
    Alvis Guzmán N; De La Hoz Restrepo F; Vivas Consuelo D
    Rev Panam Salud Publica; 2006 Oct; 20(4):248-55. PubMed ID: 17316483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemophilus influenzae type b conjugate vaccine use and effectiveness.
    Morris SK; Moss WJ; Halsey N
    Lancet Infect Dis; 2008 Jul; 8(7):435-43. PubMed ID: 18582836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain.
    Jiménez FJ; Guallar-Castillón P; Rubio Terrés C; Guallar E
    Pharmacoeconomics; 1999 Jan; 15(1):75-83. PubMed ID: 10345159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis.
    Broughton EI
    J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection.
    Hay JW; Daum RS
    Pediatrics; 1987 Sep; 80(3):319-29. PubMed ID: 3114708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New considerations for Haemophilus influenzae type b vaccination.
    Pinson JB; Weart CW
    Clin Pharm; 1992 Apr; 11(4):332-6. PubMed ID: 1563228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.